Amgen completed the acquisition of Otezla from Celgene for $13.4bn.

Amgen, an American multinational biopharmaceutical company headquartered in Thousand Oaks, California, completed the acquisition of Otezla, a medication for the treatment of certain types of psoriasis and psoriatic arthritis, from Celgene Corporation, an American biotechnology company, for $13.4bn. Celgene divested the asset in connection with its merger agreement with Bristol-Myers Squibb. "We look forward to working with the dedicated professionals joining us from Celgene to help realize the global potential of Otezla as an important option for patients," Robert A. Bradway, Amgen Chairman, and CEO.